HomeNewsBusinessStocksBuy Cipla: target of Rs 1150: Sharekhan

Buy Cipla: target of Rs 1150: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1150 in its research report dated March 31, 2022.

April 01, 2022 / 12:14 IST
Story continues below Advertisement

Sharekhan's research report on Cipla

A relentless focus on growing its India business has led to a strong show by Cipla, largely led by growth in the chronics therapies and synergies from One India Strategy. Recent price hike by NPPA, effective April 2022, could help Cipla partially mitigate cost pressures. Likely market share gains in gAlbuterol and Arformoterol Tartrate Inhalation Solution, and a strong product pipeline including complex products would fuel US sales growth. Overall based on the company’s cost control measures, savings from one India strategy, and expected improvement in US business, the overall margins are expected to expand 180 bps over FY22E to FY24E, albeit in the near-term elevated input costs and freight cost point at margin pressures.

Story continues below Advertisement

Outlook

We re-iterate Buy recommendation on Cipla with an unchanged PT of RS 1150.